“The Indian product Covishield has not been associated with any incidents of thrombosis,” Paul said. “There is no signal whatsoever for this concern. Covishield is safe, please proceed with its scale-up and uptake. We want to assure that there is no risk of blood clotting-related complications that were suspected in some nations with Covishield,” he added.
The Niti Aayog official emphasised that both vaccines — Covishield and Covaxin — currently in use in India were effective against the Brazilian and UK strains.